Site Selection

7 (Demo)

When will companies stop babysitting the NANNIs for their clinical trials? 5 key takeaways from SCOPE 2020

SCOPE continues to be a central location for industry colleagues to meet and exchange ideas around clinical development. We had a great time at the 2020 meeting catching up with friends, clients and colleagues, as well as co-moderating a roundtable on protocol design and chairing a main session on site selection with esteemed industry practitioners. It was a whirlwind of…

nash-featured-l

Delivering NASH trials in a competitive world using ClinSite

In our last blog we talked about the importance of site level insights in making solid decisions about which investigators can successfully support your trial. In this blog we give further insights about how ClinSite can support decision making on investigator site selection in NASH, a fiercely competitive space for investigator site patient enrollment. When we launched ClinSite at DIA…

site-insights-blog-1

Clinical Trial Site-Level Insights

Have you ever felt uncertain that you are selecting the right site for your study? Do you wish you had some objective insights to supplement the capabilities your potential investigator reported on the site selection survey? What if you had insights into competition at the site and investigator level? What if you knew the types of studies, interventions and outcome…

b006

Pharma and Biotech are Waiting for 21st Century Clinical Trial Data Analytics Engines

As a repository of clinical trial information, few databases are as trusted – or as widely used – as www.clinicaltrials.gov. A service of the U.S. National Library of Medicine, clinicaltrials.gov aims to provide comprehensive information on privately and publicly funded clinical studies conducted around the world. Many drug developers mine the database to facilitate decisions on trial design, investigator recruitment,…

b007

Predicting Investigator Site Enrollment Performance: Separating Myth from Truth

Throughout my two-decade career in the biopharmaceutical industry, my goal has been to make drug development more efficient while reducing costs, and to help the companies I have worked for increase revenue without compromising quality. In pursuing that goal, I have strived to embrace advanced technologies and to optimize organizational and operational structures. Now that I have joined Phesi, I…

b009

Site, Investigator, or Investigator Site?

The life sciences industry is riddled with casually used terms, acronyms and phrases which are often used out of context or defined differently among companies or individuals. This becomes especially problematic when developing and designing clinical trials, as terms that are tossed around as ‘givens’ can be much more complex processes that may dictate success or failure of a clinical…

img

KOLs: An Endangered Buzzword

The term, “key opinion leader” (supported by its well-known acronym KOL) is one of the industry’s most common buzzwords, and for good reason. Physician KOLs have always influenced treatment guidelines and practice behaviors. They have traditionally exerted their influence through research and publication on drug safety and efficacy, which, while still valuable, must now share the stage with other important…